1,618 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 1,618 shares of the company’s stock, valued at approximately $208,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Alexander Labrunerie & CO. Inc. purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $1,446,000. Garde Capital Inc. purchased a new position in Novo Nordisk A/S during the first quarter valued at $139,000. Cetera Advisor Networks LLC boosted its holdings in shares of Novo Nordisk A/S by 24.4% during the 1st quarter. Cetera Advisor Networks LLC now owns 170,897 shares of the company’s stock valued at $21,943,000 after buying an additional 33,482 shares in the last quarter. Cetera Advisors LLC grew its position in shares of Novo Nordisk A/S by 106.8% in the 1st quarter. Cetera Advisors LLC now owns 63,633 shares of the company’s stock worth $8,170,000 after buying an additional 32,862 shares during the period. Finally, Cetera Investment Advisers increased its stake in shares of Novo Nordisk A/S by 453.3% in the 1st quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock worth $34,095,000 after acquiring an additional 217,545 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, July 1st. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. Argus lifted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Stock Down 3.8 %

NVO traded down $4.97 during trading on Friday, hitting $127.49. 4,774,033 shares of the company’s stock traded hands, compared to its average volume of 3,918,008. The stock has a market capitalization of $572.12 billion, a price-to-earnings ratio of 43.96, a PEG ratio of 1.33 and a beta of 0.41. The company’s 50 day simple moving average is $138.21 and its two-hundred day simple moving average is $129.20. Novo Nordisk A/S has a 12-month low of $78.19 and a 12-month high of $148.15. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The company had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. Analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.